- Home
- HROW vs XPRO Comparison
HROW vs XPRO Comparison
Compare HROW & XPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- XPRO
- Stock Information
- Founded
- HROW 1998
- XPRO 1938
- Country
- HROW United States
- XPRO United States
- Employees
- HROW N/A
- XPRO N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- XPRO Oilfield Services/Equipment
- Sector
- HROW Health Care
- XPRO Energy
- Exchange
- HROW Nasdaq
- XPRO Nasdaq
- Market Cap
- HROW 1.1B
- XPRO 1.1B
- IPO Year
- HROW N/A
- XPRO 2013
- Fundamental
- Price
- HROW $34.93
- XPRO $9.49
- Analyst Decision
- HROW Strong Buy
- XPRO Buy
- Analyst Count
- HROW 7
- XPRO 3
- Target Price
- HROW $61.83
- XPRO $12.00
- AVG Volume (30 Days)
- HROW 368.3K
- XPRO 1.1M
- Earning Date
- HROW 08-06-2025
- XPRO 07-29-2025
- Dividend Yield
- HROW N/A
- XPRO N/A
- EPS Growth
- HROW N/A
- XPRO N/A
- EPS
- HROW N/A
- XPRO 0.58
- Revenue
- HROW $212,858,000.00
- XPRO $1,720,185,000.00
- Revenue This Year
- HROW $44.89
- XPRO N/A
- Revenue Next Year
- HROW $38.22
- XPRO $4.25
- P/E Ratio
- HROW N/A
- XPRO $16.33
- Revenue Growth
- HROW 53.49
- XPRO 10.48
- 52 Week Low
- HROW $20.85
- XPRO $6.70
- 52 Week High
- HROW $59.23
- XPRO $24.50
- Technical
- Relative Strength Index (RSI)
- HROW 70.24
- XPRO 57.44
- Support Level
- HROW $30.81
- XPRO $9.12
- Resistance Level
- HROW $33.27
- XPRO $9.61
- Average True Range (ATR)
- HROW 1.37
- XPRO 0.48
- MACD
- HROW 0.09
- XPRO 0.05
- Stochastic Oscillator
- HROW 88.78
- XPRO 91.13
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.